Table 3 Comparison of histopathopathological features in BA group versus Non-BA patients
From: Role of percutaneous liver biopsy in infantile cholestasis: cohort from Arabs
| Histopathology variables | BA group (n = 22) | All Non- BA group (n = 100) | OR[95% C.I] | P Value |
|---|---|---|---|---|
| Lobular disarray no. (%) | 0 | 11 (11) | – | 0.103 |
| Mild-mod bile duct proliferation no. (%) | 14 (63.63) | 46 (46) | 2.054 [0.792–5.331] | 0.134 |
| Marked bile duct proliferation no. (%) | 8 (36.36) | 8 (8) | 6.571 [2.123–20.34] | < 0.001* |
| Bile duct paucity/loss no. (%) | 0 | 23 (23) | – | 0.013* |
| Bile duct injury no. (%) | 4 (18.18) | 15 (15) | 1.259 [0.374–4.242] | 0.709 |
| Periductular fibrosis no. (%) | 2 (9.09) | 5 (5) | 1.9 [0.344–10.497] | 0.455 |
| Perisinosoidal fibrosis no. (%) | 0 | 11 (11) | – | 0.103 |
| Portal fibrosis no. (%) | 22 (100) | 83 (83) | – | 0.037* |
| Giant cell formation no. (%) | 4 (18.18) | 23 (23) | 0.744 [0.229–2.419] | 0.622 |
| Hepatocyte swelling no. (%) | 5(22.72) | 52 (52) | 0.271 [0.093–0.793] | 0.013* |
| Canalicular cholestasis no. (%) | 22 (100) | 73 (73) | – | 0.006* |
| Bile duct plugs no. (%) | 10 (45.45) | 3 (3) | 26.944 [6.494–111.788] | < 0.001* |
| Fatty infiltration no. (%) | 0 | 11 (11) | – | 0.103 |